Trevi Therapeutics, Inc. has named Yann Mazabraud as its Chief Commercial Officer and Head of International. Mr. Mazabraud will join Trevi’s senior management team and be responsible for overseeing Trevi’s commercial strategy and international operations. Trevi is a late-stage biopharmaceutical company focused on developing Nalbuphine® ER for chronic pruritic conditions,
“I am excited to welcome Yann to our executive leadership team,” said Jennifer L. Good, President and Chief Executive Officer of Trevi. “Trevi is advancing its lead indication into pivotal trials and expanding its pipeline into new indications where we believe Nalbuphine ER’s unique mechanism of action could be effective. Yann’s extensive experience in commercial strategy, marketing and market access in the U.S., Europe and Latin America will prove to be valuable at this important time of growth for the Company.”
With over two decades of commercial and general management experience in the biopharmaceutical industry, Mr. Mazabraud joins Trevi from an extensive career at Sanofi Genzyme where he most recently served as US General Manager and North America Head, Rare Diseases. Mr. Mazabraud has held multiple leadership positions while at Sanofi Genzyme including Vice President and Head of Latin America. In his most recent roles, he reported to the CEO and was a member of the Sanofi Genzyme Executive Leadership Team. Mr. Mazabraud holds a Masters in Management from Ecole Supérieure de Commerce de La Rochelle.
“Trevi has a unique therapeutic platform with the potential to bring new and transformative therapies to patients affected by severe diseases with currently no options,” said Mr. Mazabraud. “I’m thrilled to join a passionate team that is working relentlessly for the benefit of thousands of patients worldwide, and I look forward to contributing to Trevi’s future growth and continued success.”